Published in Eur J Cancer on July 01, 2005
Early Detection of Taxane-Induced Neuropathy in Women With Breast Cancer | NCT02549534
Neuropathy is not associated with clinical outcomes in patients receiving adjuvant taxane-containing therapy for operable breast cancer. J Clin Oncol (2012) 1.85
Chemotherapy-induced peripheral neurotoxicity. Nat Rev Neurol (2010) 1.71
An evolving cellular pathology occurs in dorsal root ganglia, peripheral nerve and spinal cord following intravenous administration of paclitaxel in the rat. Brain Res (2007) 1.49
The synthetic diazonamide DZ-2384 has distinct effects on microtubule curvature and dynamics without neurotoxicity. Sci Transl Med (2016) 1.40
Animal models of chemotherapy-evoked painful peripheral neuropathies. Neurotherapeutics (2009) 1.24
Mitochondrial abnormality in sensory, but not motor, axons in paclitaxel-evoked painful peripheral neuropathy in the rat. Neuroscience (2011) 1.10
Animal models of peripheral neuropathies. Neurotherapeutics (2012) 1.09
Modeling chemotherapeutic neurotoxicity with human induced pluripotent stem cell-derived neuronal cells. PLoS One (2015) 1.02
CR4056, a new analgesic I2 ligand, is highly effective against bortezomib-induced painful neuropathy in rats. J Pain Res (2012) 1.00
Terminal arbor degeneration--a novel lesion produced by the antineoplastic agent paclitaxel. Eur J Neurosci (2011) 1.00
Pathobiology of cancer chemotherapy-induced peripheral neuropathy (CIPN). Front Pharmacol (2013) 0.99
Fatigue and sleep during cancer and chemotherapy: translational rodent models. Comp Med (2008) 0.85
Genetic inactivation and pharmacological blockade of sigma-1 receptors prevent paclitaxel-induced sensory-nerve mitochondrial abnormalities and neuropathic pain in mice. Mol Pain (2014) 0.82
The impact of sustained and intermittent docetaxel chemotherapy regimens on cognition and neural morphology in healthy mice. Psychopharmacology (Berl) (2013) 0.81
Preparation and characterization of self-assembled nanoparticles based on low-molecular-weight heparin and stearylamine conjugates for controlled delivery of docetaxel. Int J Nanomedicine (2014) 0.79
Predictors of duloxetine response in patients with oxaliplatin-induced painful chemotherapy-induced peripheral neuropathy (CIPN): a secondary analysis of randomised controlled trial - CALGB/alliance 170601. Eur J Cancer Care (Engl) (2015) 0.78
Vasodilatation in the rat dorsal hindpaw induced by activation of sensory neurons is reduced by paclitaxel. Neurotoxicology (2010) 0.78
Pharmacogenetics, enzyme probes and therapeutic drug monitoring as potential tools for individualizing taxane therapy. Pharmacogenomics (2013) 0.77
Ixabepilone-induced mitochondria and sensory axon loss in breast cancer patients. Ann Clin Transl Neurol (2014) 0.76
Docetaxel-loaded multilayer nanoparticles with nanodroplets for cancer therapy. Int J Nanomedicine (2016) 0.76
Profound and persistent painful paclitaxel peripheral neuropathy in a premenopausal patient. BMJ Case Rep (2011) 0.75
Effects of paclitaxel on mechanical sensitivity and morphine reward in male and female C57Bl6 mice. Exp Clin Psychopharmacol (2016) 0.75
Design of theranostic nanomedicine (II): synthesis and physicochemical properties of a biocompatible polyphosphazene-docetaxel conjugate. Int J Nanomedicine (2017) 0.75
Sox2 deficiency causes neurodegeneration and impaired neurogenesis in the adult mouse brain. Development (2004) 3.75
Anti-amyloid β autoantibodies in cerebral amyloid angiopathy-related inflammation: implications for amyloid-modifying therapies. Ann Neurol (2013) 2.29
Human cutaneous melanomas lacking MITF and melanocyte differentiation antigens express a functional Axl receptor kinase. J Invest Dermatol (2011) 2.09
The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity Scale. J Peripher Nerv Syst (2007) 2.01
Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial. Lancet Neurol (2012) 1.95
Chemotherapy-induced peripheral neurotoxicity (CIPN): an update. Crit Rev Oncol Hematol (2011) 1.82
Erythropoietin both protects from and reverses experimental diabetic neuropathy. Proc Natl Acad Sci U S A (2004) 1.65
Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients. J Neurol Neurosurg Psychiatry (2013) 1.55
Effects of manidipine and delapril in hypertensive patients with type 2 diabetes mellitus: the delapril and manidipine for nephroprotection in diabetes (DEMAND) randomized clinical trial. Hypertension (2011) 1.54
Bortezomib-induced peripheral neurotoxicity: a neurophysiological and pathological study in the rat. Exp Neurol (2007) 1.54
Chemotherapy-Induced Peripheral Neurotoxicity assessment: a critical revision of the currently available tools. Eur J Cancer (2010) 1.50
Paclitaxel and Cisplatin-induced neurotoxicity: a protective role of acetyl-L-carnitine. Clin Cancer Res (2003) 1.45
Use of the alkaline in vivo Comet assay for mechanistic genotoxicity investigations. Mutagenesis (2004) 1.44
Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention. Neuro Oncol (2012) 1.44
Differentiating electrophysiological effects and cardiac safety of drugs based on the electrocardiogram: a blinded validation. Heart Rhythm (2012) 1.44
Intraepidermal nerve fiber density in rat foot pad: neuropathologic-neurophysiologic correlation. J Peripher Nerv Syst (2005) 1.37
Comparison of neuropathy-inducing effects of eribulin mesylate, paclitaxel, and ixabepilone in mice. Cancer Res (2011) 1.21
Multi-center assessment of the Total Neuropathy Score for chemotherapy-induced peripheral neurotoxicity. J Peripher Nerv Syst (2006) 1.15
Protective effect of erythropoietin and its carbamylated derivative in experimental Cisplatin peripheral neurotoxicity. Clin Cancer Res (2006) 1.15
Multimodal assessment of painful peripheral neuropathy induced by chronic oxaliplatin-based chemotherapy in mice. Mol Pain (2011) 1.12
Oxaliplatin-induced neurotoxicity is dependent on the organic cation transporter OCT2. Proc Natl Acad Sci U S A (2013) 1.08
Diabetes-induced myelin abnormalities are associated with an altered lipid pattern: protective effects of LXR activation. J Lipid Res (2011) 1.08
Retinoic acid-induced neuritogenesis of human neuroblastoma SH-SY5Y cells is ERK independent and PKC dependent. J Neurosci Res (2004) 1.08
Clinical pattern and associations of oxaliplatin acute neurotoxicity: a prospective study in 170 patients with colorectal cancer. Cancer (2012) 1.08
Interventions for preventing neuropathy caused by cisplatin and related compounds. Cochrane Database Syst Rev (2011) 1.07
Glutamate carboxypeptidase inhibition reduces the severity of chemotherapy-induced peripheral neurotoxicity in rat. Neurotox Res (2009) 1.01
CR4056, a new analgesic I2 ligand, is highly effective against bortezomib-induced painful neuropathy in rats. J Pain Res (2012) 1.00
A potent and selective S1P(1) antagonist with efficacy in experimental autoimmune encephalomyelitis. Chem Biol (2012) 0.98
Validation of the Italian version of the Neuropathic Pain Symptom Inventory in peripheral nervous system diseases. Neurol Sci (2009) 0.98
Tubulin: a target for antineoplastic drugs into the cancer cells but also in the peripheral nervous system. Curr Med Chem (2009) 0.98
Role of MAPKs in platinum-induced neuronal apoptosis. Neurotoxicology (2009) 0.97
ERK1 and ERK2 are involved in recruitment and maturation of human mesenchymal stem cells induced to adipogenic differentiation. J Mol Cell Biol (2011) 0.96
Chemotherapy-induced peripheral neurotoxicity can be misdiagnosed by the National Cancer Institute Common Toxicity scale. J Peripher Nerv Syst (2011) 0.95
Acetyl-L-Carnitine prevents and reverts experimental chronic neurotoxicity induced by oxaliplatin, without altering its antitumor properties. Anticancer Res (2005) 0.95
Bortezomib-induced painful neuropathy in rats: a behavioral, neurophysiological and pathological study in rats. Eur J Pain (2009) 0.95
Neuroactive steroids and peripheral neuropathy. Brain Res Rev (2007) 0.94
Bortezomib- and thalidomide-induced peripheral neuropathy in multiple myeloma: clinical and molecular analyses of a phase 3 study. Am J Hematol (2014) 0.93
Peripheral neurotoxicity of platinum-based chemotherapy. Nat Rev Cancer (2008) 0.93
Osteodensitometry after total hip replacement with uncemented taper-design stem. Int Orthop (2003) 0.91
Experimental validation of a commercial 3D dose verification system for intensity-modulated arc therapies. Phys Med Biol (2010) 0.91
Preclinical cardiac safety assessment of pharmaceutical compounds using an integrated systems-based computer model of the heart. Prog Biophys Mol Biol (2006) 0.91
Erythropoietin: not just about erythropoiesis. Lancet (2010) 0.90
Neurotoxicity of platinum compounds: comparison of the effects of cisplatin and oxaliplatin on the human neuroblastoma cell line SH-SY5Y. J Neurooncol (2004) 0.89
Chemotherapy-induced allodinia: neuroprotective effect of acetyl-L-carnitine. In Vivo (2005) 0.89
Cisplatin-induced peripheral neuropathy: neuroprotection by erythropoietin without affecting tumour growth. Eur J Cancer (2007) 0.89
Clinical outcome and periprosthetic bone remodelling of an uncemented femoral component with taper design. Int Orthop (2003) 0.88
Effect of the chronic combined administration of cisplatin and paclitaxel in a rat model of peripheral neurotoxicity. Eur J Cancer (2008) 0.88
Glutamate transporters in platelets: EAAT1 decrease in aging and in Alzheimer's disease. Neurobiol Aging (2004) 0.88
Mesenchymal stem cells neuronal differentiation ability: a real perspective for nervous system repair? Curr Stem Cell Res Ther (2011) 0.88
Paclitaxel toxicity in post-mitotic dorsal root ganglion (DRG) cells. Anticancer Res (2006) 0.88
NGF protects dorsal root ganglion neurons from oxaliplatin by modulating JNK/Sapk and ERK1/2. Neurosci Lett (2010) 0.88
Expression and distribution of 'high affinity' glutamate transporters GLT1, GLAST, EAAC1 and of GCPII in the rat peripheral nervous system. J Anat (2008) 0.88
Experimental epothilone B neurotoxicity: results of in vitro and in vivo studies. Neurobiol Dis (2009) 0.87
Role of a pre-existing neuropathy on the course of bortezomib-induced peripheral neurotoxicity. J Peripher Nerv Syst (2008) 0.86
Immunogenicity without immunoselection: a mutant but functional antioxidant enzyme retained in a human metastatic melanoma and targeted by CD8(+) T cells with a memory phenotype. Cancer Res (2005) 0.86
Site-specific effects of ghrelin on the neuronal activity in the hypothalamic arcuate nucleus. Neurosci Lett (2003) 0.86
Emerging role of mitogen-activated protein kinases in peripheral neuropathies. J Peripher Nerv Syst (2007) 0.86
Docetaxel-induced peripheral neuropathy: protective effects of dihydroprogesterone and progesterone in an experimental model. J Peripher Nerv Syst (2009) 0.86
Bortezomib-induced painful peripheral neuropathy: an electrophysiological, behavioral, morphological and mechanistic study in the mouse. PLoS One (2013) 0.86
Bortezomib-induced peripheral neurotoxicity: an update. Arch Toxicol (2014) 0.85
Optimization of the in vitro cardiac safety of hydroxamate-based histone deacetylase inhibitors. J Med Chem (2011) 0.84
Valproate protective effects on cisplatin-induced peripheral neuropathy: an in vitro and in vivo study. Anticancer Res (2008) 0.84
MAP kinase modulation in squamous cell carcinoma of the oral cavity. Anticancer Res (2009) 0.84
Increased spinal cord NGF levels in rats with cobalamin (vitamin B12) deficiency. Neurosci Lett (2005) 0.84
Activation of the liver X receptor increases neuroactive steroid levels and protects from diabetes-induced peripheral neuropathy. J Neurosci (2010) 0.84
Association between metalloproteinases 2 and 9 activity and ERK1/2 phosphorylation status in head and neck cancers: an ex vivo study. Oncol Rep (2010) 0.83
Epothilone-induced peripheral neuropathy: a review of current knowledge. J Pain Symptom Manage (2011) 0.83
Neurotoxic effects of antineoplastic drugs: the lesson of pre-clinical studies. Front Biosci (2008) 0.83
Continuous buprenorphine delivery effect in streptozotocine-induced painful diabetic neuropathy in rats. J Pain (2009) 0.83